Imbria Pharmaceuticals, a privately held clinical-stage biotechnology company focused on innovative treatments for cardiometabolic diseases. Has announced the closing of a $57.5 million Series B financing round. The raise was led by new investor Deep Track Capital. With additional participation from AN Ventures, Catalio Capital Management, and Cytokinetics, Inc. Existing backers RA Capital Management and SV Health Investors also contributed to the round.
Imbria is advancing a pipeline of novel therapies designed to address diseases characterized by impaired cellular energy production. Akey driver of symptoms and disease progression in many cardiometabolic disorders.
The company’s lead candidate, ninerafaxstat, is a next-generation metabolic modulator that has completed multiple Phase 2 trials across three indications:
- Non-obstructive hypertrophic cardiomyopathy (nHCM)
- Stable angina
- Heart failure with preserved ejection fraction (HFpEF)
Clinical data from Phase 1 and 2 trials have shown that ninerafaxstat is well tolerated, supporting its continued development as a potential treatment for patients with limited therapeutic options.
“This financing underscores the confidence of top-tier life science investors in our mission to transform treatment for patients living with cardiometabolic diseases,” said a spokesperson for Imbria. “We’re excited to advance ninerafaxstat through additional clinical development and further explore its potential to improve cellular energetics and quality of life in these underserved populations.”
